A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study

导出原文传递

翻译打印收藏纠错

作者： Dizon, Don S. ^[1] ; Sill, Michael W. ^[2] ; Schilder, Jeanne M. ^[3] ; McGonigle, Kathryn F. ^[4] ; Rahman, Zia ^[5] ; Miller, David S. ^[6] ; Mutch, David G. ^[7] ; Leslie, Kimberly K.

作者单位： Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA ^[1] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA ^[2] Washington Univ, Sch Med, St Louis, MO USA ^[3] Indiana Univ, Med Ctr, Indianapolis, IN USA ^[4] Roswell Pk Canc Inst, Stat & Data Ctr, NRG Oncol Gynecol Oncol Grp, Buffalo, NY 14263 USA ^[5] St Francis Hosp & Med Ctr, Hartford, CT USA ^[6] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA ^[7]

关键词 Endometrial cancer Angiogenesis inhibitor Clinical trial

发布时间 2015-03-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交